Table 3.
Distribution of CTRCD Diagnosis at Different Time Points According to Different Troponin Upper Reference Limit
| Baselinea (n = 120) | After 1 Cycle (n = 115) | After Anthracyclines (n = 115) | After Trastuzumab or Radiation Therapy (n = 81) | Extended Follow-Up (n = 103) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex-specific cTnI | |||||||||||
| No CTRCD | CTRCD | No CTRCD | CTRCD | No CTRCD | CTRCD | No CTRCD | CTRCD | No CTRCD | CTRCD | ||
| Sex-specific cTnT | No CTRCD | 118 (98) | 0 (0) | 113 (98) | 1 (1) | 60 (52) | 0 (0) | 68 (84) | 1 (1) | 92 (89) | 0 (0) |
| CTRCD | 2 (2) | 0 (0) | 1 (1) | 0 (0) | 43 (37) | 12 (10) | 8 (10) | 4 (5) | 7 (7) | 4 (4) | |
| Sex-neutral cTnI | |||||||||||
| No CTRCD | CTRCD | No CTRCD | CTRCD | No CTRCD | CTRCD | No CTRCD | CTRCD | No CTRCD | CTRCD | ||
| Sex-neutral cTnT | No CTRCD | 120 (100) | 0 (0) | 115 (100) | 0 (0) | 90 (78) | 1 (1) | 75 (93) | 0 (0) | 99 (96) | 0 (0) |
| CTRCD | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 18 (16) | 6 (5) | 3 (4) | 3 (4) | 0 (0) | 4 (4) | |
Values are n (%). The table is to be interpreted as follows: 118 of 120 patients at baseline were defined as “no CTRCD” by both sex-specific cTnT and cTnI; 2 patients fulfilled the CTRCD criteria defined by sex-specific cTnT but not cTnI.
cTn = cardiac troponin; CTRCD = cancer therapy–related cardiac dysfunction.
a
At baseline, we report the number and percentage of patients who fulfilled the CTRCD criteria prior to the initiation of adjuvant therapy.